— Fundamental Stock Analysis and Report Card
Located in Secaucus, NJ, US. Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 2.9b +243.0m +9.2% | |
| Gross Income | 942.0m +79.0m +9.2% | 33% +0.0pp +0.0% |
| EBITDA | 434.0m -54.0m -11.1% | 15% -3.4pp -18.5% |
| Operating Income | 399.0m +53.0m +15.3% | 14% +0.7pp +5.6% |
| Net Income | 252.0m +32.0m +14.5% | 9% +0.4pp +4.9% |
| Earnings Per Share | 2.27 +0.3 +15.2% | |
| Operating Cash Flow | 278.0m -36.0m -11.5% | 10% -2.2pp -18.9% |
| Free Cash Flow | 164.0m -33.0m -16.8% | 6% -1.8pp -23.7% |
| Research & Development | n/a n/a n/a | n/a n/a n/a |